glp-1 receptor agonist for weight loss Agonists as Treatments Type 2 Diabetes Comparing GLP-type therapies for weight

18 Exendin-4, a GLP-1 analogue, also elicits protection against neuroinflammation, which is linked to a decrease in stroke risk

A 2023 JAMA study associates GLP-1 agonists with an increased risk of several conditions, including gastroparesis

Studies were excluded if they focused on pediatric populations, only reported emergency procedures, lacked a control group of GLP-1RA nonusers, or used limited International Classification of Diseases, Tenth Revision, and Clinical Modification (ICD-10-CM) codes for aspiration outcomes

[DOI] [PMC free article] [PubMed] [Google Scholar] 133.Rosenstock J, Wysham C, Fras JP, Kaneko S, Lee CJ, et al

The Beneficiaries of GLP-1 Drugs Across Industries Health Insurers and the Cost of Obesity Source: McKinsey 4 Although weight loss has been the main focus in the analyses of these drugs so far, it is important to bear in mind that with them comes the improvement in other measurements of health, such as blood glucose levels, cardiovascular parameters, cholesterol and triglyceride levels

These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent